glp3.wiki
Investigational · not FDA approved

Editorially reviewed · Last updated September 8, 2026 · How we review

When Will Retatrutide Be Available?

When Will Retatrutide Be Available?

Retatrutide is not an approved prescription medicine. Lilly says access is limited to its clinical trials. Its latest announced milestone is a planned FDA Biologics License Application (BLA) in Q1 2027, stated on July 23, 2026. A filing plan is not an approval or pharmacy-release date.

There is no confirmed commercial availability date. Lilly says it is completing the manufacturing and controls package for the application. FDA review and any eventual launch still lie ahead.

Timeline at a Glance

MilestoneDateWhat is known
TRIUMPH-4 topline resultsDecember 2025Reported by Lilly
TRIUMPH-1 topline resultsMay 2026Reported by Lilly; detailed presentation followed in June
TRIUMPH-2 and TRIUMPH-3 topline resultsJuly 23, 2026Reported by Lilly
BLA submission to FDAQ1 2027Lilly's stated plan; application not yet submitted
FDA decisionNot announcedDepends on the application and review
Commercial launchNot announcedRequires approval and a launch announcement

The TRIUMPH Phase 3 Program

The initial registration program includes TRIUMPH-1 through TRIUMPH-4. Lilly has reported positive results from all four. Additional trials address other populations and questions, including a comparison with tirzepatide and longer-term cardiovascular and kidney outcomes.

For study-specific recruitment status and dates, use the clinical trial tracker and each linked registry record. A study's estimated completion date is not an approval date.

Why TRIUMPH-1 Is the Most Important

TRIUMPH-1 is the pivotal registration trial with 2,339 randomized participants and an 80-week treatment duration — longer than TRIUMPH-4's 68 weeks. It reported on May 21, 2026: 28.3% average weight loss at 12 mg over 80 weeks, and 30.3% at 104 weeks in a pre-specified extension. These are efficacy-estimand results, which estimate outcomes had participants remained on treatment without prohibited weight-management therapy. The extension applies to an eligible subset. Lilly describes a submission package supported by several trials.

TRIUMPH-3 Status

TRIUMPH-3 studies weight management in adults with severe obesity and established cardiovascular disease. Lilly reported topline results on July 23, 2026: 22.6% average weight loss at 12 mg and 21.6% at 9 mg over 80 weeks, versus 3.2% on placebo. The ClinicalTrials.gov registry results record had not yet been posted. It is not the event-driven cardiovascular outcomes trial; that is the separate TRIUMPH-Outcomes study. Full detail: TRIUMPH-3 results.

FDA Review Process

Standard and Priority Review

FDA describes a 10-month standard review goal and a six-month priority review goal. These are review goals, not guarantees that an application will be approved. There is no announced FDA review designation or decision date for retatrutide.

Potential Delays

Lilly must first complete and submit its application. FDA may request additional information during review. The current public evidence does not establish whether a particular adverse event will trigger an advisory committee or how many months any issue might add.

Three Scenarios

The meaningful distinction is between Lilly's planned filing, FDA's eventual decision, and commercial availability. Only the first has an announced target. Assigning an optimistic, base-case or conservative launch year would add a forecast that neither Lilly nor FDA has confirmed.

How to Access Retatrutide Today

Lilly says retatrutide is available only through its clinical trials. To find a study:

Typical Eligibility Criteria

Eligibility varies by trial and site. Check the specific record and contact the study team rather than assuming a universal BMI threshold or medication washout period. Do not stop an existing treatment to qualify without discussing it with your clinician and the study team.

See clinical trial signup for the application process.

Grey Market Is Not a Safe Alternative

FDA says retatrutide cannot be used in compounding under federal law and warns against unapproved products sold as research chemicals for human use. A seller's label or certificate does not establish an approved medicine. See grey-market risks.

What Happens After Approval

Approval, pharmacy supply and insurance coverage are separate milestones. Lilly has not announced a retatrutide launch schedule, distribution plan or savings program in the sources reviewed here.

Expected Pricing

There is no announced approved-product price. Prices of other medicines cannot establish what retatrutide will cost. See cost and access for updates.

International Availability

Lilly says its trial package supports global submissions, but the July announcement gives a target date for the US filing only. It does not provide confirmed approval or launch dates for Europe, the UK, Canada or other markets. Check the relevant national regulator and Lilly's local announcements before treating a date as confirmed.

Frequently Asked Questions

Is retatrutide available now?

Lilly says access is limited to clinical trials. It is not an approved prescription medicine.

When will retatrutide be FDA approved?

No date is confirmed. Lilly plans to submit its BLA in Q1 2027. Submission does not guarantee approval or establish a launch date.

Can my doctor prescribe retatrutide?

There is no FDA-approved retatrutide product to prescribe. FDA also says retatrutide cannot be used in compounding under federal law.

Will insurance cover retatrutide?

Coverage and any savings program have not been announced. They cannot be inferred from Lilly's other products.

What should I do while waiting?

Discuss currently approved treatments with your clinician, or check an official retatrutide study's eligibility criteria and recruitment status.

Sources

Questions to ask your doctor

  • Is an approved GLP-1 medication a reasonable option for me?
  • How can I access a legitimate, prescribed option safely?
  • What are the specific risks of unregulated or compounded sources?
  • What monitoring or follow-up would I need if I started treatment?

How we keep this honest
What this is
Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status
Retatrutide and similar peptides are investigational — not approved by the FDA or any regulator. Semaglutide and tirzepatide are prescription-only medicines, available only through a licensed prescriber.
Our standard
Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties
We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Sources

Grounded in primary sources
NEJMThe LancetJAMAFDAClinicalTrials.gov